Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial
(2018)
Journal Article
Varlet, P., Mackay, A., Burford, A., Molinari, V., Jones, D. T., Izquierdo, E., Brouwer-Visser, J., Giangaspero, F., Haberler, C., Pietsch, T., Jacques, T. S., Figarella-Branger, D., Rodriguez, D., Morgan, P. S., Raman, P., Waanders, A. J., Resnick, A. C., Massimino, M., Garrè, M. L., Smith, H., …Jones, C. (2018). Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial. Cancer Cell, 33(5), 829-842.e5. https://doi.org/10.1016/j.ccell.2018.04.004
The HERBY trial was a phase II open-label, randomized, multicenter trial evaluating bevacizumab (BEV) in addition to temozolomide/radiotherapy in patients with newly diagnosed non-brainstem high-grade glioma (HGG) between the ages of 3 and 18 years.... Read More about Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial.